Sarcopenia Determines the Success of Immunotherapy in Advanced Lung Cancer
Korea University Guro Hospital and Seoul National University College of Pharmacy Research Team
Suggests Potential for New Prognostic Indicators
A recent study has found that immunotherapy, one of the treatments for advanced non-small cell lung cancer (NSCLC), is less effective in patients with sarcopenia.
(From the left) Chuhwan Choi and Seungryong Lee, Professors of Respiratory and Allergy Medicine at Korea University Guro Hospital; Jieun Park, Ph.D., and Youngki Shin, Professors at Seoul National University College of Pharmacy. Korea University Guro Hospital
View original imageOn June 26, Korea University Guro Hospital announced that a joint research team led by Professors Chuhwan Choi and Seungryong Lee of the Department of Respiratory and Allergy Medicine at Korea University Guro Hospital, along with Jieun Park, PhD, and Professor Youngki Shin of Seoul National University College of Pharmacy, has confirmed that sarcopenia can serve as an important predictor of immunotherapy outcomes in patients with advanced NSCLC.
Although immunotherapy is a representative treatment for advanced NSCLC, treatment outcomes vary from patient to patient, and there has been a consistent need to discover new predictive indicators.
To address this, the research team analyzed 74 patients with advanced NSCLC who received immunotherapy (immune checkpoint inhibitors) as first-line treatment, examining the presence of sarcopenia and immune/inflammatory markers in their blood, and investigated the relationship between these factors and treatment results. Muscle mass was measured to determine the presence of sarcopenia, and inflammatory responses and changes in immune cells were analyzed from blood samples.
The results showed that patients with sarcopenia experienced faster cancer progression and a shorter duration of effectiveness from immunotherapy (immune checkpoint inhibitors) compared to those without sarcopenia. Additionally, sarcopenia was identified as an independent predictor of poorer prognosis in patients receiving immunotherapy.
The research team reported that patients with sarcopenia exhibited more active inflammatory responses, as well as higher expression of 'TIGIT,' a protein associated with reduced immune cell function. Notably, patients with both sarcopenia and high TIGIT expression had the worst treatment outcomes.
Professor Chuhwan Choi stated, "This study confirmed that sarcopenia can be an important predictor of immunotherapy outcomes in patients with advanced non-small cell lung cancer," adding, "We expect that assessing both sarcopenia and blood biomarkers in the future will help establish personalized treatment strategies for each patient."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
This research was published in the international journal 'Scientific Reports' under the title, "Impact of Sarcopenia and Blood Biomarkers on Prognosis in Patients with Advanced Non-Small Cell Lung Cancer Receiving First-Line Immune Checkpoint Inhibitor Therapy."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.